Laguno, MVon Wichmann, MAVan den Eynde, ENavarro, JCifuentes Luna, CarmenMurillas Angoiti, JavierVeloso, SMartinez-Rebollar, MGuardiola, JMJou, AGomez-Sirvent, J. LCervantes, MPineda, JALopez-Calvo, SCarrero, AMontes, MLDeig, ElisabethTapiz, ARuiz-Mesa, JDCruceta, Ade Lazzari, EllsaMallolas, J2024-07-092024-07-092016-12Laguno M, Von Wichmann MA, Van Den Eynde E, Navarro J, Cifuentes Luna C, Murillas Angoiti J, et al. Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study. Int J Infect Dis. 2016 Dec;53:46-51. Epub 2016 Nov 1.1201-9712http://hdl.handle.net/20.500.13003/17296http://hdl.handle.net/20.500.12105/20233Introduction: Boceprevir (BOC) was one of the first oral inhibitors of hepatitis C virus (HCV) NS3 protease to be developed. This study assessed the safety and efficacy of BOC + pegylated interferon-alpha 2a/ribavirin (PEG-IFN/RBV) in the retreatment of HIV-HCV co-infected patients with HCV genotype 1. Methods: This was a phase III prospective trial. HIV-HCV (genotype 1) co-infected patients from 16 hospitals in Spain were included. These patients received 4 weeks of PEG-IFN/RBV (lead-in), followed by response-guided therapy with PEG-IFN/RBV plus BOC (a fixed 44 weeks was indicated in the case of cirrhosis). The primary endpoint was the sustained virological response (SVR) rate at 24 weeks post-treatment. Efficacy and safety were evaluated in all patients who received at least one dose of the study drug. Results: From June 2013 to April 2014, 102 patients were enrolled, 98 of whom received at least one treatment dose. Seventy-three percent were male, 34% were cirrhotic, 23% had IL28b CC, 65% had genotype 1a, and 41% were previous null responders. The overall SVR rate was 67%. Previous null-responders and cirrhotic patients had lower SVR rates (57% and 51%, respectively). Seventy-six patients (78%) completed the therapy scheme; the most common reasons for discontinuation were lack of response at week 12 (12 patients) and adverse events (six patients). Conclusions: Response-guided therapy with BOC in combination with PEG-IFN/RBV led to an overall SVR rate of 67%, but an SVR rate of only 51% in patients with cirrhosis. The therapy was generally well tolerated. Although the current standards of care do not include BOC + PEG-IFN/RBV, the authors believe that this combination can be beneficial in situations where new HCV direct antiviral agent interferonfree therapies are not available yet.enghttp://creativecommons.org/licenses/by-nc-nd/4.0/PEG-IFN/RBV plus BOC therapyHIV-HCV experienced patientsHCV genotype 1Re-treatmentViral Nonstructural ProteinsGenotypeHepacivirusRetreatmentPolyethylene GlycolsSpainAdultAntiviral AgentsHepatitis CHumansDrug Therapy, CombinationMiddle AgedRecombinant ProteinsHIV InfectionsMaleProspective StudiesFemaleCoinfectionTreatment OutcomeProlineInterferon-alphaRibavirinresearch articleAttribution-NonCommercial-NoDerivatives 4.0 International278152255346-5110.1016/j.ijid.2016.10.0281878-3511International Journal of Infectious Diseasesopen accessProlinaResultado del TratamientoCoinfecciónPolietilenglicolesInterferón-alfaFemeninoInfecciones por VIHMasculinoQuimioterapia CombinadaHepatitis CHumanosPersona de Mediana EdadEstudios ProspectivosGenotipoProteínas RecombinantesProteínas no Estructurales ViralesAntiviralesAdultoRibavirinaHepacivirusRetratamientoEspaña2-s2.0-84997050481389516700011L613310152